Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Buy

Debt to Equity Rating

Neutral

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Buy

Insider Trading

Strong Sell

Wall Street Data Solutions Rating

Buy

A

Regeneron Pharmaceuticals Inc (REGN)

Pharmaceutical Preparations

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/02/1991

Market Cap

127,975,426,800

Shares Outstanding

107,130,000

Weighted SO

108,946,984

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

CRSP --.--%

NVO --.--%

SRPT --.--%

NTLA --.--%

INCY --.--%

ALNY --.--%

UTHR --.--%

RARE --.--%

APLS --.--%

Beta

0.1280

Last Div

0.0000

Range

769.19-1182.38

Chg

5.0701

Avg Vol

451283

Mkt Cap

127975426800

Exch

NASDAQ

Country

US

Phone

914 847 7000

DCF Diff

-1775.4789

DCF

2955.7489

Div Yield

0.0000

P/S

9.4873

EV Multiple

28.8582

P/FV

4.5239

Div Yield %

0.0000

P/E

29.5257

PEG

2.9354

Payout

0.0000

Current Ratio

5.4385

Quick Ratio

4.6195

Cash Ratio

0.5496

DSO

154.6983

DIO

558.5898

Op Cycle

713.2881

DPO

109.1870

CCC

604.1011

Gross Margin

0.8608

Op Margin

0.2918

Pretax Margin

0.3401

Net Margin

0.3204

Eff Tax Rate

0.0579

ROA

0.1198

ROE

0.1630

ROCE

0.1208

NI/EBT

0.9421

EBT/EBIT

1.1655

EBIT/Rev

0.2918

Debt Ratio

0.0550

D/E

0.0703

LT Debt/Cap

0.0657

Total Debt/Cap

0.0657

Int Coverage

2186.6111

CF/Debt

2.0521

Equity Multi

1.2794

Rec Turnover

2.3594

Pay Turnover

3.3429

Inv Turnover

0.6534

FA Turnover

3.1327

Asset Turnover

0.3738

OCF/Share

37.6549

FCF/Share

29.6790

Cash/Share

90.8094

OCF/Sales

0.3018

FCF/OCF

0.7882

CF Coverage

2.0521

ST Coverage

0.0000

CapEx Coverage

4.7211

Div&CapEx Cov

4.7211

P/BV

4.5239

P/B

4.5239

P/S

9.4873

P/E

29.5257

P/FCF

39.8889

P/OCF

31.3478

P/CF

31.3478

PEG

2.9354

P/S

9.4873

EV Multiple

28.8582

P/FV

4.5239

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 07, 22:30 Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color GlobeNewswire Inc. May 30, 05:00 Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO GlobeNewswire Inc. May 30, 05:00 Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials GlobeNewswire Inc. May 30, 05:00 Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies The Motley Fool Mar 25, 22:47 Why Pharma and Biotech Stocks Got Thrashed on Tuesday GlobeNewswire Inc. Mar 12, 01:32 Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem GlobeNewswire Inc. Mar 01, 20:13 REGN ?????????????????? ROSEN ???? 10 ?????? Regeneron Pharmaceuticals, Inc. ????? REGN ??????????????? 3 ? 10 ?????? GlobeNewswire Inc. Mar 01, 20:13 REGN FINAL DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 27, 01:10 REGN DEADLINE ALERT: Regeneron Pharmaceuticals (REGN) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class Action GlobeNewswire Inc. Feb 23, 19:03 ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 21, 00:26 ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 19, 00:53 REGN STOCK NEWS: Robbins LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025 GlobeNewswire Inc. Feb 18, 05:59 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP) GlobeNewswire Inc. Feb 12, 23:57 Analyst Cuts Regeneron Pharmaceuticals (REGN) Price Target After Sales Concerns and Investor Lawsuit– Hagens Berman GlobeNewswire Inc. Feb 12, 02:04 ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 09, 04:34 ROSEN, A LEADING LAW FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Feb 08, 22:40 EYLEA HD® (aflibercept) Injection 8 mg Positive Phase 3 Results in Patients with Macular Edema following Retinal Vein Occlusion Presented at Angiogenesis Meeting GlobeNewswire Inc. Feb 08, 20:55 Three-Year Results for EYLEA HD® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals GlobeNewswire Inc. Jan 29, 02:02 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN GlobeNewswire Inc. Jan 19, 16:13 ROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN

Revenue Product Segmentation